The TRANSFORM network is focused on improving child health outcomes in SC through research on conditions of highest priority for future generations. These include conditions like asthma, autism, diabetes, obesity and early childhood outcomes. To accelerate research study recruitment activities for future projects that TRANSFORM sites may participate in, the TRANSFORM network sites will create a research recruitment registry of families interested in volunteering for research. Participants will enter their own as well as their child(ren)'s information into the electronic registry which can be used to identify people to contact for future studies.
The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance the understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Male and female patients 1 year to 45 years of age who are first and second/third degree relatives of individuals with type 1 diabetes may be eligible to participate in this study.
Palmetto Health/USC Department of Pediatrics, Division of Pediatric Endocrinology
9 Richland Medical Park
Columbia, SC 29203
Study Site Principal Investigator Contact Information:
Lisa Knight, MD at 803-434-7990
The purpose of this research study is to learn more about the outcomes of total pancreatectomy with islet autotransplantation (TPIAT). Total pancreatectomy is the removal of the pancreas and islet autotransplantation is the placement of the insulin producing cells back into you to prevent diabetes. This study is looking to enroll patients who are scheduled to have a TPIAT surgery to treat pancreatitis (inflammation and scarring of the pancreas).
In addition to the routine care for pancreatitis and TPIAT surgery, participation in this study will involve completion of some brief surveys about the subject's health before TPIAT, at 6 months after TPIAT, and each year after the TPIAT surgery for 4 years, as well as a lab test conducted at each of the follow-up visits.
The purpose of this study is to test whether treatment with a drug called alpha 1 antitrypsin (AAT, Prolastin, Grilfols, Inc.) can reduce the chance of getting diabetes in a specific situation. Sometimes patients have their pancreas gland removed for pain. Since the pancreas makes insulin from cells called islet cells, these are removed from the pancreas and returned to the body to try decrease the chance of diabetes. The only participants invited to this study are those individuals getting ready to have the pancreas surgery.
Individuals with venous leg and diabetic foot ulcers often find these ulcers take a long time to heal and when they do, sometimes they come back. These ulcers can be quite painful making it hard to work, sleep and go about one's day to day activities. You will be asked to do a self-care routine of taking the temperature of the skin where the leg or foot ulcer just healed with a special thermometer and applying a small cooling gel patch over this skin. We want to know if this routine will prevent the ulcer from coming back, help you to become more active, and improve the quality of your life.
Autologous islet cell transplantation, which means islet cells will be separated from patient?s pancreas and transplanted back to the same patient, is currently performed in chronic pancreatitis patients after removal of their pancreases. However, more than 50-60% of islet cells die right after transplantation due to stresses generated during the peri-transplant period. We have observed in animal studies that harvesting islets using mediums bubbled with low dose of carbon monoxide (CO) gas can protect islets from death after transplantation. In this study, we plan to use CO bubbled mediums to harvest patient?s islets, so that more islet cells can survive after transplantation. Thus, patients can be diabetes free or requires less insulin treatment even they do get diabetes.
Patients with Type 2 diabetes often have more gum disease. The bacteria is the gut help to determine the body's immune system and may influence both gum disease and diabetes. This project will look at the impact of the oral bacteria on the gut bacteria in patients with both diabetes and gum disease compared with control subjects.
Research study looking for participants with high triglycerides and either cardiovascular disease or risk factors for cardiovascular disease (e.g.history of heart attack, stroke, stent placement or diabetes type 1 or 2.) This study is being carried out to see if a new investigational drug called Epanova® when added to current treatment for high cholesterol, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect). Medications, all study visits, blood work and study procedures are free of charge.
The purpose of this study is to investigate sphingolipids, a very biologically active class of lipids transported in lipoproteins, in patients with diabetes who have kidney disease (nephropathy). Lipoproteins are particles in blood which transport not only cholesterol and fats but also sphingolipids. Lipoproteins also play an important role in the development of diabetes complications, including nephropathy. This study will investigate the role of the sphingolipids in VLDL (Very Low Density Lipoprotein), LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) in the development of nephropathy in diabetes.
This study is providing annual blood tests looking at diabetes autoantibodies for first degree relatives of patients diagnosed with type 1 diabetes who are between the ages of 1 and 45. It will also provide "diabetes screening" for second and third degree relatives age 1-20. Often parents and/or relatives wonder "if they will get diabetes" down the road or if additional offspring are "at risk" for type 1 diabetes. This study aims at assisting families with free blood testing. If positive, participants will be eligible for "prevention studies". MUSC is currently only participating in the "screening or Natural History" portion of TrialNet.